AEGiS-Reuters: Medizone delays HIV/AIDS treatment trial

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Medizone delays HIV/AIDS treatment trial

Reuters NewMedia, Inc.; Tuesday December 2, 8:02 am EST

SALT LAKE CITY, Dec 2 (Reuters) - Medizone International Inc, a maker of a treatment for HIV/AIDS and Hepatitis B, said Tuesday it would begin an aggressive clinical trial program in Italy during the second quarter -- instead of during the first quarter as originally planned -- because of significant design changes it says should enhance the product and future revenues.

The company said in a statement the initial Phase I trial conducted in healthy adults will test the safety, tolerance and toxicity of the Medizone, patented ``thin-film'' ozone technology and delivery system.

Phase II trials will follow, testing the efficacy of Medizone in treating HIV/AIDS and Hepatitis B patients. The initial Phase II trials will address the pharmacokinetics of the current antiretroviral drugs ZDV, 3TC and Indinavir used on patients during concomitant administration of Medizone.

Medizone said it expects that the antiretroviral activity of Medizone, as demonstrated in previous animal studies, will prove to be an adjunct to existing therapies and will prolong and improve quality of life.

It also said an agreement with JRH Biosciences of Lenexa, Kan., announced April 22, has been cancelled.

971202
RE971205

Copyright © 1997 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .